How Biotech sponsors can accelerate clinical development of early stage interventions

As the global elderly population grows, the urgency to address unmet Alzheimer's disease (AD) treatment needs intensifies. Biotech and emerging biopharma companies are at the forefront of developing novel therapies aimed at disrupting AD pathology before extensive irreversible damage occurs. Biotech sponsors can optimize trials by leveraging, diagnostic advances — particularly newly characterized blood plasma biomarkers — and novel protocol designs. This white paper explores how collaborations with a clinical research organization with deep expertise in neurology and AD can unlock opportunities for sponsors to successfully operationalize AD clinical trials and bring transformative therapies to patients faster.